Who
Susan M. Podlogar
Director
Company insider
Files Form 4 as: Director, Tevogen; Director, LivaNova; EVP & Chief HR Officer, MetLife.
In numbers
- Trades disclosed
- 60
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $216K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 10 Jul 2017
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | TVGN TevogenBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | TVGN TevogenBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | TVGN TevogenBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 10 Jul 2026filed 10 Jul 2026 | TVGN TevogenBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code M | —4,042 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code F | $39K486 at $79.70 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code M | —4,042 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code M | —4,042 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,383 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,383 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code M | —4,042 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code F | $39K486 at $79.70 | filing |
| 15 Dec 2025filed 17 Dec 2025 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code M | —2,355 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code M | —2,355 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | LIVN LivaNovaMedical Devices | SEC FORM 4 Code F | $17K269 at $63.06 | filing |
| 15 Jun 2025filed 17 Jun 2025 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code A | —4,042 at $0.00 | filing |
| 23 Dec 2024filed 26 Dec 2024 | TVGN TevogenBiotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 15 Dec 2024filed 17 Dec 2024 | LIVN LivaNovaoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,355 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | MET MetLifeInsurance | SEC FORM 4 Code F | $133K1,907 at $69.73 | filing |
| 27 Feb 2024filed 29 Feb 2024 | MET MetLifeoption or derivative · Insurance | SEC FORM 4 Code A | —12,040 at $0.00 | filing |
News
MetLife (NYSE:MET) Given New $114.00 Price Target at TD CowenMET · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Susan M. Podlogar; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.